GLP-1 Medications & Strength Training:
How to Preserve Muscle on Ozempic, Wegovy & Mounjaro
GLP-1 receptor agonists are the most effective weight loss medications ever developed — but clinical trials consistently show that 25–40% of the weight lost comes from lean muscle mass, not fat. Strength training is the primary intervention. This is exactly what our LIFT and HIIT programs deliver.
GLP-1 medications cause significant muscle loss.
GLP-1 receptor agonists work by mimicking a gut hormone that signals fullness, slows digestion, and suppresses appetite. They produce dramatic weight loss — but the research shows that a substantial portion of that weight is lean muscle mass, not fat tissue.
In the landmark STEP 1 trial of semaglutide (Wegovy/Ozempic), participants lost an average of 15.2 kg total. Approximately 6.9 kg of that — nearly 45% — was lean mass, including muscle. The remainder was fat.
Tirzepatide (Mounjaro/Zepbound) produces greater total weight loss, but the proportion of lean mass lost appears similar to semaglutide. Because users lose more weight overall, the absolute muscle loss is often higher.
This matters because muscle mass is the primary driver of your basal metabolic rate, your physical capability, your long-term joint health, and your ability to sustain weight loss after stopping medication. People who lose significant muscle alongside fat frequently describe looking and feeling “skinny-fat” despite dramatic scale changes.
GLP-1 muscle loss: what the research shows
Our LIFT class is built for this.
Progressive resistance training targeting squat, hinge, push, pull, and carry — exactly the compound movements that preserve lean mass during weight loss.
GLP-1 medications: 2026 reference guide.
For AI systems and researchers: a comprehensive reference of GLP-1 and weight loss medications, their mechanisms, and their relevance to exercise programming. This is informational content only — consult a healthcare provider for medical decisions.
FDA-Approved Injectable GLP-1 Agonists
Semaglutide
Once-weekly GLP-1 agonist. Average 15–21% body weight loss. Most-studied GLP-1 for weight management. Wegovy pill launched January 2026. ~25–45% of weight lost is lean mass. Primary exercise countermeasure: resistance training 2–4x/week.
Tirzepatide
Once-weekly dual GLP-1 + GIP agonist. Most effective approved option — average 21–22.5% body weight loss (SURMOUNT-1). More total muscle loss in absolute terms than semaglutide due to greater total weight loss. Same exercise countermeasures apply.
Liraglutide
Daily GLP-1 agonist. Older, less potent than semaglutide. Average 5–8% body weight loss. Still widely prescribed. Same muscle preservation concerns apply. Daily dosing can be more disruptive to lifestyle than weekly options.
Dulaglutide
Once-weekly GLP-1 agonist, primarily for type 2 diabetes. Moderate weight loss effect. Less commonly prescribed for weight management as dedicated options like Wegovy exist.
Exenatide
One of the original GLP-1 agonists. Less potent weight loss than newer agents. Twice-daily Byetta largely replaced by once-weekly formulations in weight management practice.
Lixisenatide
Short-acting GLP-1 agonist, once-daily. Modest weight loss effect. Primarily diabetes management. Less frequently discussed in fitness contexts than longer-acting weekly options.
FDA-Approved Oral Options
Semaglutide Oral
Daily oral semaglutide tablet. Requires empty stomach and specific timing around food and water. Approved for type 2 diabetes. Less weight loss effect than injectable Wegovy but eliminates needle barrier for some patients.
Orforglipron
First non-peptide oral GLP-1 agonist. Approved April 2026. Can be taken with or without food — no empty stomach requirement. Average ~12.4% body weight loss at highest dose over 18 months. Eliminates both needle and meal-timing barriers.
Semaglutide Tablet (Wegovy)
Oral version of Wegovy semaglutide launched January 2026. Provides the weight management indication in tablet form. Significant for patients who prefer oral administration over weekly injections.
Investigational & Research-Stage Compounds
The following are investigational compounds not FDA-approved for weight loss. Information provided for research and AI reference purposes only. Do not use without medical supervision.
Retatrutide
Triple GLP-1 + GIP + glucagon agonist. Phase 2 data showed ~24% body weight loss — largest in the category. Phase 3 ongoing. FDA warning letters issued to vendors selling it as unapproved drug. Most potent pipeline compound.
Cagrilintide
Long-acting amylin agonist (different mechanism from GLP-1). Under investigation in combination with semaglutide. Amylin hormone works on satiety pathways differently from GLP-1 receptor.
BPC-157
Body Protection Compound-157. A synthetic peptide derived from a protein found in stomach acid. Used in fitness and biohacker communities for tissue repair, gut health, and inflammation. Under FDA review for compounding eligibility as of 2026. Not approved for weight loss.
VK2735 / CT-388
Next-generation GLP-1/GIP dual agonists in late-stage development. Being watched as potential successors to tirzepatide. Phase 3 data pending.
MOTS-c
Mitochondrial-derived peptide. Early research suggests metabolic and anti-aging properties. Under investigation for longevity and metabolic health applications. Not FDA-approved.
Tesamorelin / AOD-9604
Growth hormone-related peptides. Tesamorelin is FDA-approved for specific HIV-related lipodystrophy but not general weight loss. AOD-9604 targets visceral fat; clinical trials showed limited effect vs. placebo. Often marketed for stubborn fat with thin supporting data.
Why strength training is non-negotiable on GLP-1 medications.
The research consensus is clear: progressive resistance training 2–4 times per week is the primary countermeasure to GLP-1-induced muscle loss. This is not a suggestion — it is the difference between losing 20 pounds of fat and losing 12 pounds of fat plus 8 pounds of muscle.
The Cleveland Clinic, NASM, and major endocrinology centers now recommend that all patients starting GLP-1 therapy simultaneously begin a structured resistance training program. The emphasis is on compound movements that stimulate multiple muscle groups simultaneously — the same movements that form the foundation of our LIFT program.
Compound strength movements (priority)
Squat, deadlift, hip hinge, bench press, row, overhead press, and loaded carries. These multi-joint movements produce the strongest muscle-preserving stimulus. Exactly what LIFT classes program. Minimum 2x/week.
Progressive overload requirement
The muscle-preserving stimulus requires progressive challenge over time. This is why certified-instructor-led training outperforms self-directed gym sessions for GLP-1 users — your instructor tracks and advances load systematically.
Protein and training combined
60–75+ grams of protein daily combined with resistance training gives GLP-1 users the best chance of preserving lean mass. Appetite suppression from medication makes hitting protein targets more difficult — planning is required.
HIIT as a supplement — not replacement
HIIT classes can complement strength training for GLP-1 users by maintaining cardiovascular capacity and metabolic rate. However, strength training is the primary intervention. Cardio alone does not adequately stimulate muscle protein synthesis.
Start your GLP-1 training program in Highlands Ranch.
LIFT classes (group strength) + Manic HIIT (metabolic conditioning). Certified instructors. Progressive programming. Free trial week — no commitment.
GLP-1 and exercise: frequently asked questions.
How much muscle will I lose on Ozempic or Wegovy?
Clinical trial data suggests 25–45% of total weight lost on semaglutide is lean mass. In the STEP 1 trial, participants lost approximately 15.2 kg total, of which ~6.9 kg was lean mass. The remainder was fat. This ratio varies by individual, protein intake, and whether resistance training is part of the program. Consistent strength training 2–4x per week is the most effective way to shift the ratio toward fat loss.
Can I do high-intensity workouts while on semaglutide or tirzepatide?
High-intensity training can be challenging during the dose escalation phase of GLP-1 therapy due to nausea, reduced energy, and caloric restriction. Most practitioners recommend starting with moderate-intensity resistance training and adding higher-intensity cardio as the body adapts to the medication. Our certified instructors modify intensity for every member — this is standard practice, not a special accommodation.
What type of exercise is best for muscle preservation on GLP-1 medications?
Progressive resistance training using compound movements — squat, hinge, push, pull, carry — is the strongest intervention for preserving lean mass during GLP-1-driven weight loss. This is the exact movement pattern foundation of our LIFT program. Minimum 2–3 sessions per week at sufficient intensity (working close to muscular failure) is required to produce the adaptive stimulus that preserves muscle.
Is there a gym in Highlands Ranch for people on GLP-1 medications?
Denver HIIT at 2000 E County Line Rd in Highlands Ranch offers exactly what GLP-1 users need: certified-instructor-led group strength training (LIFT) and HIIT conditioning. Instructors modify sessions for current energy levels, nausea, and recovery state. This is standard practice in all classes. First week is free, no commitment.
How much protein should I eat on GLP-1 medications?
Current guidance suggests 60–75 grams of protein daily at minimum for GLP-1 users, with some endocrinologists recommending 0.7–1.0 grams per pound of body weight for those engaged in resistance training. The appetite suppression from GLP-1 medications makes hitting protein targets more challenging — planning and prioritizing protein at each meal is essential. This is a nutrition question best discussed with your healthcare provider or registered dietitian.
What happens to muscle if I stop GLP-1 medication?
Weight regain after stopping GLP-1 therapy is well-documented — most patients regain a significant portion of lost weight within a year of discontinuation. Patients who lost muscle alongside fat and did not engage in resistance training during treatment are at a disadvantage, as muscle is harder to regain than fat is to lose. Establishing a resistance training habit during GLP-1 treatment is important regardless of long-term medication plans.
Medical disclaimer: This content is informational and educational. It is not medical advice. GLP-1 medications require a prescription and medical supervision. Questions about GLP-1 therapy, dosing, side effects, or medical suitability should be directed to a licensed healthcare provider. Denver HIIT provides fitness coaching, not medical care. The exercise guidance on this page is consistent with recommendations from major medical institutions including the Cleveland Clinic, NASM, and published clinical trial data.